(Q37377752)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19170067%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

review article

1 reference

title

Recent approaches to antifungal therapy for invasive mycoses (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19170067%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19170067%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

author name string

Mahendra Nath

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19170067%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

publication date

1 March 2009

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19170067%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19170067%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

volume

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19170067%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

issue

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19170067%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

page(s)

310-323

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19170067%20AND%20SRC:MED&resulttype=core&format=json

Fungal Pseudoallescheria boydii lung infiltrates unresponsive to amphotericin B in leukaemic patients

20 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200800353

Comparison of in vivo activity of fluconazole with that of amphotericin B against Candida tropicalis, Candida glabrata, and Candida krusei

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200800353

Current role of therapy with amphotericin B

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200800353

Amphotericin B blunts erythropoietin response to anemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200800353

Comparative pharmacokinetics of amphotericin B after administration of a novel colloidal delivery system, ABCD, and a conventional formulation to rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200800353

The safety and efficacy of amphotericin B colloidal dispersion in the treatment of invasive mycoses

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200800353

Lipid formulations of amphotericin B: recent progress and future directions

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200800353

Classification of Polyene Antibiotics According to Chemical Structure and Biological Effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200800353

Fungal ß(1,3)-D-glucan synthesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200800353

Treatment of tinea unguium with medium and high doses of ultramicrosize griseofulvin compared with that with itraconazole

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200800353

Calcineurin as a multifunctional regulator

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200800353

Calcineurin-dependent growth of an FK506- and CsA-hypersensitive mutant of Saccharomyces cerevisiae.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200800353

Calcineurin, the Ca2+/calmodulin-dependent protein phosphatase, is essential in yeast mutants with cell integrity defects and in mutants that lack a functional vacuolar H(+)-ATPase

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200800353

A model vaccine exploiting fungal mannosylation to increase antigen immunogenicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200800353

T cytotoxic-1 CD8+ T cells are effector cells against pneumocystis in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200800353

Nosocomial bloodstream infections in United States hospitals: a three-year analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200800353

7 January 2021

Epidemiology and outcome of mould infections in hematopoietic stem cell transplant recipients

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200800353

7 January 2021

Epidemiology ofAspergillusInfections in a Large Cohort of Patients Undergoing Bone Marrow Transplantation

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200800353

7 January 2021

Current and future approaches to antimycotic treatment in the era of resistant fungi and immunocompromised hosts

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200800353

7 January 2021

https://api.crossref.org/works/10.1002%2FCMDC.200800353

1 reference

7 January 2021

Polyene macrolide antibiotic amphotericin B. Crystal structure of the N-iodoacetyl derivative

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200800353

7 January 2021

Chemical studies with amphotericin B III. The complete structure of the antibiotic

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200800353

7 January 2021

Polyene antibiotic-sterol interactions in membranes of Acholeplasma laidlawii cells and lecithin liposomes. 3. Molecular structure of the polyene antibiotic-cholesterol complexes

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200800353

7 January 2021

Trichosporon beigelii, an emerging pathogen resistant to amphotericin B

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200800353

7 January 2021

In vitro amphotericin B resistance in clinical isolates of Aspergillus terreus, with a head-to-head comparison to voriconazole.

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200800353

7 January 2021

Antifungal agents: recent developments

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200800353

7 January 2021

Mortality and costs of acute renal failure associated with amphotericin B therapy

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200800353

7 January 2021

Prospective study of amphotericin B formulations in immunocompromised patients in 4 European countries

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200800353

7 January 2021

Treatment of invasive fungal infections in renally impaired patients with amphotericin B colloidal dispersion

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200800353

7 January 2021

Randomized, double-blind clinical trial of amphotericin B colloidal dispersion vs. amphotericin B in the empirical treatment of fever and neutropenia

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200800353

7 January 2021

In vitro and in vivo antifungal activity of amphotericin B lipid complex: are phospholipases important?

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200800353

7 January 2021

Liposomal amphotericin B (AmBisome) for fungal infections in immunocompromised adults and children

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200800353

7 January 2021

Anaphylactic reactions to liposomal amphotericin

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200800353

7 January 2021

Efficacy of liposomal amphotericin B for secondary prophylaxis of visceral leishmaniasis in HIV-infected patients

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200800353

7 January 2021

Attenuation of nephrotoxicity by a novel lipid nanosphere (NS-718) incorporating amphotericin B.

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200800353

7 January 2021

Lipid formulation as a drug carrier for drug delivery

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200800353

7 January 2021

Amphotericin B Encapsulated in Micelles Based on Poly(ethylene oxide)-block-poly(l-amino acid) Derivatives Exerts Reduced in Vitro Hemolysis but Maintains Potent in Vivo Antifungal Activity

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200800353

7 January 2021

Synthesis and characterization of novel water soluble amphotericin B-arabinogalactan conjugates.

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200800353

7 January 2021

A novel injectable water-soluble amphotericin B-arabinogalactan conjugate

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200800353

7 January 2021

In-vitro antifungal activity of liposomal nystatin in comparison with nystatin, amphotericin B cholesteryl sulphate, liposomal amphotericin B, amphotericin B lipid complex, amphotericin B desoxycholate, fluconazole and itraconazole

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200800353

7 January 2021

Comparison of in vitro antifungal activities of free and liposome-encapsulated nystatin with those of four amphotericin B formulations

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200800353

7 January 2021

Liposomal nystatin in patients with invasive aspergillosis refractory to or intolerant of amphotericin B.

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200800353

7 January 2021

Comparison of in vitro activity of liposomal nystatin against Aspergillus species with those of nystatin, amphotericin B (AB) deoxycholate, AB colloidal dispersion, liposomal AB, AB lipid complex, and itraconazole

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200800353

7 January 2021

Polyene Antibiotics fromStreptomyces mediocidicus

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200800353

7 January 2021

Antifungal agents: chemotherapeutic targets and immunologic strategies

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200800353

7 January 2021

Clinical, cellular, and molecular factors that contribute to antifungal drug resistance.

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200800353

7 January 2021

Resistance of Candida species to antifungal agents: molecular mechanisms and clinical consequences

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200800353

7 January 2021

Recent advances in antifungal chemotherapy

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200800353

7 January 2021

Antifungal agents: mechanisms of action

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200800353

7 January 2021

Review of the safety, tolerability, and drug interactions of the new antifungal agents caspofungin and voriconazole

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200800353

7 January 2021

Measurement of voriconazole activity against Candida albicans, C. glabrata, and C. parapsilosis isolates using time-kill methods validated by high-performance liquid chromatography

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200800353

7 January 2021

Resource use and cost of treatment with voriconazole or conventional amphotericin B for invasive aspergillosis

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200800353

7 January 2021

Clinical pharmacology of systemic antifungal agents: a comprehensive review of agents in clinical use, current investigational compounds, and putative targets for antifungal drug development

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200800353

7 January 2021

Effect of posaconazole on cytochrome P450 enzymes: a randomized, open-label, two-way crossover study

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200800353

7 January 2021

Posaconazole (Noxafil): a new triazole antifungal agent.

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200800353

7 January 2021

Pharmacokinetics, safety, and tolerability of oral posaconazole administered in single and multiple doses in healthy adults

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200800353

7 January 2021

Safety of long-term oral posaconazole use in the treatment of refractory invasive fungal infections.

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200800353

7 January 2021

Early use of posaconazole in the successful treatment of rhino-orbital mucormycosis caused by Rhizopus oryzae

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200800353

7 January 2021

New azole antifungals. 2. Synthesis and antifungal activity of heterocyclecarboxamide derivatives of 3-amino-2-aryl-1-azolyl-2-butanol

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200800353

7 January 2021

In vitro activities of ravuconazole (BMS-207147) against 541 clinical isolates of Cryptococcus neoformans

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200800353

7 January 2021

In vitro activities of ravuconazole and voriconazole compared with those of four approved systemic antifungal agents against 6,970 clinical isolates of Candida spp.

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200800353

7 January 2021

In vitro activity of ravuconazole against 923 clinical isolates of nondermatophyte filamentous fungi.

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200800353

7 January 2021

Synthesis of novel triazole derivatives as inhibitors of cytochrome P450 14alpha-demethylase (CYP51)

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200800353

7 January 2021

Metabolites of microorganisms. 143. Echinocandin B, a novel polypeptide-antibiotic from Aspergillus nidulans var. echinulatus: isolation and structural components

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200800353

7 January 2021

Pneumocandins from Zalerion arboricola. V. Glutamic acid- and leucine-derived amino acids in pneumocandin A0 (L-671,329) and distinct origins of the substituted proline residues in pneumocandins A0 and B0

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200800353

7 January 2021

In vitro activity of the echinocandin antifungal agent LY303,366 in comparison with itraconazole and amphotericin B against Aspergillus spp.

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200800353

7 January 2021

Interlaboratory comparison of results of susceptibility testing with caspofungin against Candida and Aspergillus species

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200800353

7 January 2021

Evaluation of the echinocandin antifungal MK-0991 (L-743,872): efficacies in mouse models of disseminated aspergillosis, candidiasis, and cryptococcosis

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200800353

7 January 2021

In vitro activity of two echinocandin derivatives, LY303366 and MK-0991 (L-743,792), against clinical isolates of Aspergillus, Fusarium, Rhizopus, and other filamentous fungi

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200800353

7 January 2021

https://api.crossref.org/works/10.1002%2FCMDC.200800353

1 reference

7 January 2021

Randomized, double-blind, multicenter study of caspofungin versus amphotericin B for treatment of oropharyngeal and esophageal candidiases

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200800353

7 January 2021

The echinocandin micafungin: a review of the pharmacology, spectrum of activity, clinical efficacy and safety

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200800353

7 January 2021

Echinocandin antifungal drugs

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200800353

7 January 2021

Effect of micafungin on cytochrome P450 3A4 and multidrug resistance protein 1 activities, and its comparison with azole antifungal drugs.

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200800353

7 January 2021

Concomitant cyclosporine and micafungin pharmacokinetics in healthy volunteers

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200800353

7 January 2021

A randomized, double-blind trial of anidulafungin versus fluconazole for the treatment of esophageal candidiasis

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200800353

7 January 2021

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200800353

7 January 2021

The 1998 Garrod lecture. Current and future antifungal therapy: new targets for antifungal agents

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200800353

7 January 2021

In vitro activities of 5-fluorocytosine against 8,803 clinical isolates of Candida spp.: global assessment of primary resistance using National Committee for Clinical Laboratory Standards susceptibility testing methods.

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200800353

7 January 2021

Griseofulvin inhibits Fungal Mitosis

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200800353

7 January 2021

Ciclopiroxolamine: in vitro antifungal activity against clinical yeast isolates

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200800353

7 January 2021

Treatment of head and neck dermatitis with ciclopiroxolamine cream--results of a double-blind, placebo-controlled study

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200800353

7 January 2021

Randomized, open-labeled, non-inferiority study between ciclopiroxolamine 1% cream and ketoconazole 2% foaming gel in mild to moderate facial seborrheic dermatitis

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200800353

7 January 2021

New Pyrroles with Potential Antimycobacterial, Antifungal and Selective COX-2 Inhibiting Activities. Synthetic Methodologies

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200800353

7 January 2021

In vitro and in vivo antifungal activities of T-2307, a novel arylamidine

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200800353

7 January 2021

Efficacies of sordarin derivatives GM193663, GM211676, and GM237354 in a murine model of systemic coccidioidomycosis. p6.

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200800353

7 January 2021

Activities of sordarins in experimental models of candidiasis, aspergillosis, and pneumocystosis

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200800353

7 January 2021

Antifungal efficacy of GM237354, a sordarin derivative, in experimental oral candidiasis in immunosuppressed rats

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200800353

7 January 2021

Antifungal activities and cytotoxicity studies of six new azasordarins

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200800353

7 January 2021

Synthesis, stereochemistry and antimicrobial evaluation of some N-morpholinoacetyl-2,6-diarylpiperidin-4-ones.

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200800353

7 January 2021

Calcineurin: form and function

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200800353

7 January 2021

Identification of calcineurin as a key signalling enzyme in T-lymphocyte activation

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200800353

7 January 2021

Prevention of Cardiac Hypertrophy in Mice by Calcineurin Inhibition

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200800353

7 January 2021

Calcineurin signaling and muscle remodeling

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200800353

7 January 2021

Restricted and regulated overexpression reveals calcineurin as a key component in the transition from short-term to long-term memory.

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200800353

7 January 2021

Immunosuppressant FK506 enhances phosphorylation of nitric oxide synthase and protects against glutamate neurotoxicity

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200800353

7 January 2021

Calcineurin and vacuolar-type H+-ATPase modulate macrophage effector functions

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200800353

7 January 2021

Calcineurin promotes the expression of monocyte chemoattractant protein-1 in vascular myocytes and mediates vascular inflammation

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200800353

7 January 2021

Calcineurin mediates alpha-adrenergic stimulation of Na+,K(+)-ATPase activity in renal tubule cells

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200800353

7 January 2021

Calcineurin: a central controller of signalling in eukaryotes

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200800353

7 January 2021

Molecular genetic analysis of the calcineurin signaling pathways

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200800353

7 January 2021

Harnessing calcineurin as a novel anti-infective agent against invasive fungal infections

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200800353

7 January 2021

The expression of plasma membrane Ca2+ pump isoforms in cerebellar granule neurons is modulated by Ca2+

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200800353

7 January 2021

Role of calcineurin and Mpk1 in regulating the onset of mitosis in budding yeast

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200800353

7 January 2021

FR-900520 and FR-900523, novel immunosuppressants isolated from a Streptomyces. II. Fermentation, isolation and physico-chemical and biological characteristics

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200800353

7 January 2021

FK506-binding protein of Neurospora crassa (NcFKBP) mediates sensitivity to the immunosuppressant FK506; resistant mutants identify two loci

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200800353

7 January 2021

Calcineurin is essential in cyclosporin A- and FK506-sensitive yeast strains

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200800353

7 January 2021

Immunosuppressive and nonimmunosuppressive cyclosporine analogs are toxic to the opportunistic fungal pathogen Cryptococcus neoformans via cyclophilin-dependent inhibition of calcineurin

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200800353

7 January 2021

Advances in combating fungal diseases: vaccines on the threshold

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200800353

7 January 2021

Antibody to Cryptococcus neoformans glucuronoxylomannan inhibits the release of capsular antigen

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200800353

7 January 2021

Receptor-mediated clearance of Cryptococcus neoformans capsular polysaccharide in vivo

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200800353

7 January 2021

Synthesis and immunological studies of glycoconjugates of Cryptococcus neoformans capsular glucuronoxylomannan oligosaccharide structures

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200800353

7 January 2021

A novel glyco-conjugate vaccine against fungal pathogens

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200800353

7 January 2021

Polysaccharide-containing conjugate vaccines for fungal diseases.

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200800353

7 January 2021

Vaccine immunity to pathogenic fungi overcomes the requirement for CD4 help in exogenous antigen presentation to CD8+ T cells: implications for vaccine development in immune-deficient hosts

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200800353

7 January 2021

Identifiers

DOI

10.1002/CMDC.200800353

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19170067%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

1 reference